Table 1: Baseline and treatment response factors predictive of sustained remission in the double-blind phase in the active treatment groups.
| Predictor |
Quartiles of Response, n/N (%) |
p-value* |
| Reduced-Dose Combination Therapy |
| First DAS28 remission, day |
13–57 |
58–179 |
180–273 |
≥274 |
|
| n/N (%) |
12/15 (80) |
16/20 (80) |
8/16 (50) |
4/12 (33) |
<0.01 |
| First DAS28 LDA, day |
1–29 |
30–57 |
58–183 |
≥184 |
|
| n/N (%) |
12/14 (86) |
12/20 (60) |
10/15 (67) |
6/14 (43) |
<0.05 |
| Mean DAS28, week 52 |
≤1.55 |
>1.55−1.91 |
>1.91−2.16 |
>2.16 |
|
| n/N (%) |
14/16 (88) |
11/16 (69) |
7/15 (47) |
8/16 (50) |
<0.05 |
| Methotrexate Monotherapy |
| Age, BL, years |
19–39 |
40–48 |
49–60 |
≥61 |
|
| n/N (%) |
11/15 (73) |
8/22 (36) |
2/15 (13) |
5/13 (38) |
<0.05 |
| CRP level, week 52, mg/L |
0–0.50 |
>0.50–1.09 |
>1.09–2.91 |
>2.91 |
|
| n/N (%) |
9/16 (56) |
8/14 (57) |
6/18 (33) |
2/16 (13) |
<0.01 |
* Mantel–Haenszel chi-square correlation (trend) test (univariate).
BL: baseline; CRP: C-Reactive Protein; DAS28: Disease Activity Score for 28-joint counts; LDA: Low Disease Activity.